Fragile X spectrum disorders

Intractable and Rare Diseases Research

Volumn 3, Issue 4, 2014, Pages 134-146

  Lozano, Reymundo ^a   Rosero, Carolina Alba ^b   Hagerman, Randi J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Instituto Colombiano del Sistema Nervioso   (Colombia)

Author keywords

Autism spectrum disorder; Developmental delay; Fragile X syndrome; Intellectual disability; Premutation

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ALLELE; CLINICAL FEATURE; FMR1 GENE; FRAGILE X SPECTRUM DISORDER; FRAGILE X SYNDROME; GENE MUTATION; GENETIC RISK; GENOTYPE; HUMAN; PHENOTYPE; REVIEW;

EID: 84937441486     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2014.01022     Document Type: Review

References (161)

1. Yrigollen CM, Martorell L, Durbin-Johnson B, Naudo M, Genoves J, Murgia A, Polli R, Zhou L, Barbouth D, Rupchock A, Finucane B, Latham GJ, Hadd A, Berry-Kravis E, Tassone F. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. J Neurodev Disord. 2014; 6:24.
2. Lubs HA. A marker X chromosome. Am J Hum Genet. 1969; 21:231-244.
3. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991; 65:905-914.
4. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science. 1991; 252:1097-1102.
5. Darnell JC, Richter JD. Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol. 2012; 4:a012344.
6. de Vries BB, Wiegers AM, Smits AP, Mohkamsing S, Duivenvoorden HJ, Fryns JP, Curfs LM, Halley DJ, Oostra BA, van den Ouweland AM, Niermeijer MF. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet. 1996; 58:1025-1032.
7. Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: Historical, physical, cognitive, and cytogenetic features. Am J Med Genet. 1991; 38:269-274.
8. Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011; 29:299-307.
9. Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, Yadav-Shah M, Sherman SL. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005; 20:402-412.
10. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001; 57:127-130.
11. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003; 72:869-878.
12. Jacquemont S, Farzin F, Hall D, Leehey M, Tassone F, Gane L, Zhang L, Grigsby J, Jardini T, Lewin F, Berry-Kravis E, Hagerman PJ, Hagerman RJ. Aging in individuals with the FMR1 mutation. Am J Ment Retard. 2004; 109:154-164.
13. Rodriguez-Revenga L, Madrigal I, Badenas C, Xunclà M, Jiménez L, Milà M. Premature ovarian failure and fragile X female premutation carriers: No evidence for a skewed X-chromosome inactivation pattern. Menopause. 2009; 16:944-949.
14. Hagerman P. Fragile X-associated tremor/ataxia syndrome (FXTAS): Pathology and mechanisms. Acta Neuropathologica. 2013; 126:1-19.
15. Hunsaker MR, Greco CM, Spath MA, Smits AP, Navarro CS, Tassone F, Kros JM, Severijnen LA, Berry-Kravis EM, Berman RF, Hagerman PJ, Willemsen R, Hagerman RJ, Hukema RK. Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol. 2011; 122:467-479.
16. Roberts JE, Bailey DB, Mankowski J, Ford A, Sideris J, Weisenfeld LA, Heath TM, Golden RN. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet. 2009; 150:130-139.
17. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry. 2011; 72:175-182.
18. Besterman AD, Wilke SA, Mulligan TE, Allison SC, Hagerman R, Seritan AL, Bourgeois JA. Towards an understanding of neuropsychiatric manifestations in fragile X premutation carriers. Future Neurol. 2014; 9:227-239.
19. Au J, Akins RS, Berkowitz-Sutherland L, Tang HT, Chen Y, Boyd A, Tassone F, Nguyen DV, Hagerman R. Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. 2013; 84:546-551.
20. Hamlin AA, Sukharev D, Campos L, Mu Y, Tassone F, Hessl D, Nguyen DV, Loesch D, Hagerman RJ. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A. 2012; 158A:1304-1309.
21. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman RJ. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008; 146:1009-1016.
22. Winarni TI, Chonchaiya W, Sumekar TA, Ashwood P, Morales GM, Tassone F, Nguyen DV, Faradz SM, Van de Water J, Cook K, Hamlin A, Mu Y, Hagerman PJ, Hagerman RJ. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A. 2012; 158A:2473-2481.
23. Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet. 2011; 156B:923-928.
24. Summers SM, Cogswell J, Goodrich JE, Mu Y, Nguyen DV, Brass SD, Hagerman RJ. Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation. Clin Genet. 2014; 86:181-184.
25. Soontarapornchai K, Maselli R, Fenton-Farrell G, Tassone F, Hagerman PJ, Hessl D. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol. 2008; 65:495-498.
26. Apartis E, Blancher A, Meissner WG, et al. FXTAS: New insights and the need for revised diagnostic criteria. Neurology. 2012; 79:1898-1907.
27. Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the united states. Genome Med. 2012; 4:100.
28. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013; 12:786-798.
29. Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DB Jr. Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile X syndrome. Am J Med Genet A. 2014; 164A:141-155.
30. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet. 1993; 4:335-340.
31. Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am. 1990; 72:889-896.
32. Pyeritz RE, Stamberg J, Thomas GH, Bell BB, Zahka KG, Bernhardt BA. The marker Xq28 syndrome ("fragile-X SYndrome") in a retarded man with mitral valve prolapse. Johns Hopkins Med J. 1982; 151:231-237.
33. Loesch DZ, Huggins R, Hay DA, Gedeon AK, Mulley JC, Sutherland GR. Genotype-phenotype relationships in fragile X syndrome: A family study. Am J Hum Genet. 1993; 53:1064-1073.
34. Loesch DZ, Huggins RM, Bui QM, Taylor AK, Hagerman RJ. Relationship of deficits of FMR1 gene specific protein with physical phenotype of fragile X males and females in pedigrees: A new perspective. Am J Med Genet A. 2003; 118A:127-134.
35. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004; 10:31-41.
36. McLennan Y, Polussa J, Tassone F, Hagerman R. Fragile x syndrome. Curr Genomics. 2011; 12:216-224.
37. Nowicki ST, Tassone F, Ono MY, Ferranti J, Croquette MF, Goodlin-Jones B, Hagerman RJ. The prader-willi phenotype of fragile X syndrome. J Dev Behav Pediatr. 2007; 28:133-138.
38. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB. Seizures in fragile X syndrome: Characteristics and comorbid diagnoses. Am J Intellect Dev Disabil. 2010; 115:461-472.
39. Bernard PB, Castano AM, O'Leary H, Simpson K, Browning MD, Benke TA. Phosphorylation of FMRP and alterations of FMRP complex underlie enhanced mLTD in adult rats triggered by early life seizures. Neurobiol Dis. 2013; 59:1-17.
40. Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet. 2008; 16:666-672.
41. Kaufmann WE, Abrams MT, Chen W, Reiss AL. Genotype, molecular phenotype, and cognitive phenotype: Correlations in fragile X syndrome. Am J Med Genet. 1999; 83:286-295.
42. Schneider A, Seritan A, Tassone F, Rivera SM, Hagerman R, Hessl D. Psychiatric features in high-functioning adult brothers with fragile X spectrum disorders. Prim Care Companion CNS Disord. 2013; 15. pii: PCC.12l01492.
43. Munir F, Cornish KM, Wilding J. Nature of the working memory deficit in fragile-X syndrome. Brain Cogn. 2000; 44:387-401.
44. Wilding J, Cornish K, Munir F. Further delineation of the executive deficit in males with fragile-X syndrome. Neuropsychologia. 2002; 40:1343-1349.
45. Cornish KM, Munir F, Cross G. Spatial cognition in males with fragile-X syndrome: Evidence for a neuropsychological phenotype. Cortex. 1999; 35:263-271.
46. Hall SS, Burns DD, Lightbody AA, Reiss AL. Longitudinal changes in intellectual development in children with fragile X syndrome. J Abnorm Child Psychol. 2008; 36:927-939.
47. Finestack LH, Richmond EK, Abbeduto L. Language development in individuals with fragile X syndrome. Top Lang Disord. 2009; 29:133-148.
48. Bennetto L PB. Neuropsychology. In: Fragile X syndrome: Diagnosis, treatment, and research. 3rd ed., The Johns Hopkins University Press, Baltimore, Maryland, USA, 2002.
49. Klaiman C. Quintin EM, Jo B, Lightbody AA, Hazlett HC, Piven J, Hall SS, Reiss AL. Longitudinal profiles of adaptive behavior in fragile X syndrome. Pediatrics. 2014; 134:315-324.
50. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Gen Med. 2008; 10:4-12.
51. Hatton DD, Sideris J, Skinner M, Mankowski J, bailey DBJ, Roberts J, Mirrett P. Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006; 140A:1804-1813.
52. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman RJ. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008; 113:427-438.
53. Hagerman RJ, Hagerman PJ. Fragile X syndrome: Diagnosis, treatment, and research. 3rd ed., The Johns Hopkins University Press, Baltimore, Maryland, USA, 2002; p.540.
54. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, Goodlin-Jones BL. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009; 5:145-150.
55. Gould EL, Loesch DZ, Martin MJ, Hagerman RJ, Armstrong SM, Huggins RM. Melatonin profiles and sleep characteristics in boys with fragile X syndrome: A preliminary study. Am J Med Genet. 2000; 95:307-315.
56. Cornish K, Turk J, Hagerman R. The fragile X continuum: New advances and perspectives. J Intellect Disabil Res. 2008; 52:469-482.
57. Roberts JE, Mankowski JB, Sideris J, Goldman BD, Hatton DD, Mirrett PL, Baranek GT, Reznick JS, Long AC, Bailey DB Jr. Trajectories and predictors of the development of very young boys with fragile X syndrome. J Pediatr Psychol. 2009; 34:827-836.
58. Frolli A, Piscopo S, Conson M. Developmental changes in cognitive and behavioural functioning of adolescents with fragile-X syndrome. J Intellect Disabil Res. 2014. doi: 10.1111/jir.12165.
59. Hare EB, Hagerman RJ, Lozano R. Targeted treatments in fragile X syndrome. Expert Opin Orphan Drugs. 2014; 2:531-543.
60. Braun K, Segal M. FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb Cortex. 2000; 10:1045-1052.
61. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex. 2000; 10:1038-1044.
62. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001; 107:477-487.
63. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27:370-377.
64. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. J Neurosci. 2005; 25:5087-5095.
65. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012; 122:4314-4322.
66. Massey PV, Bashir ZI. Long-term depression: Multiple forms and implications for brain function. Trends Neurosci. 2007; 30:176-184.
67. Dölen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther. 2010; 127:78-93.
68. Kumar D, Bhattacharya A, Nadel J, Moulton K, Zeak NM, Glicksman A, Dobkin C, Brick DJ, Schwartz PH, Smith CB, Klann E, Usdin K. Identification of fragile X syndrome-specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic drugs. Hum Mutat. 2014; 35:1485-1494.
69. Matic K, Eninger T, Bardoni B, Davidovic L, Macek B. Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides new insights into FMRP-dependent signal transduction mechanisms. J Proteome Res. 2014; 13:4388-4397.
70. Rubenstein JL, Merzenich MM. Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003; 2:255-267.
71. Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis i n neurodevelopmental disorder models. Front Synaptic Neurosci. 2010; 2:4.
72. Lozano R, Hare EB, Hagerman RJ. Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatr Dis Treat. 2014; 10:1769-1779.
73. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. J Neurodev Disord. 2011; 3:57-67.
74. Kwan KY, Lam MM, Johnson MB, et al. Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell. 2012; 149:899-911.
75. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, Froehner SC, Bredt DS. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 1996; 84:757-767.
76. Hölscher C. Nitric oxide, the enigmatic neuronal messenger: Its role in synaptic plasticity. Trends Neurosci. 1997; 20:298-303.
77. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev. 2000; 32:476-509.
78. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AMG. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007; 8:766-775.
79. Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist. 2010; 16:435-452.
80. Colvin SM, Kwan KY. Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders. Front Genet. 2014; 5:239.
81. Louhivuori V, Vicario A, Uutela M, Rantamäki T, Louhivuori LM, Castrén E, Tongiorgi E, Akerman KE, Castrén ML. BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis. 2011; 41:469-480.
82. Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, Pertovaara A, Akerman K, Castrén E, Castrén ML. Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav. 2012; 11:513-523.
83. Uutela M, Lindholm J, Rantamäki T, Umemori J, Hunter K, Võikar V, Castrén ML. Distinctive behavioral and cellular responses to fluoxetine in the mouse model for fragile X syndrome. Front Cell Neurosci. 2014; 8:150.
84. Todd PK, Mack KJ, Malter JS. The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc Natl Acad Sci U S A. 2003; 100:14374-14378.
85. Bechara EG, Didiot MC, Melko M, Davidovic L, Bensaid M, Martin P. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol. 2009; 7:e16.
86. Fähling M, Mrowka R, Steege A, Kirschner KM, Benko E, Förstera B, Persson PB, Thiele BJ, Meier JC, Scholz H. Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J Biol Chem. 2009; 284:4255-4266.
87. Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: Conserved RNP family domains and selective RNA binding. Science. 1993; 262:563-566.
88. Bassell GJ, Warren ST. Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron. 2008; 60:201-214.
89. Usdin K, Hayward BE, Kumari D, Lokanga RA, Sciascia N, Zhao XN. Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the fragile X-related disorders. Front Genet. 2014; 5:226.
90. Smith SS, Laayoun A, Lingeman RG, Baker DJ, Riley J. Hypermethylation of telomere-like foldbacks at codon 12 of the human c-ha-ras gene and the trinucleotide repeat of the FMR-1 gene of fragile X. J Mol Biol. 1994; 243:143-151.
91. Bulut-Karslioglu A, Perrera V, Scaranaro M, de la Rosa-Velazquez IA, van de Nobelen S, Shukeir N, Popow J, Gerle B, Opravil S, Pagani M, Meidhof S, Brabletz T, Manke T, Lachner M, Jenuwein T. A transcription factor-based mechanism for mouse heterochromatin formation. Nat Struct Mol Biol. 2012; 19:1023-1030.
92. Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, Disney MD, Jaffrey SR. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014; 343:1002-1005.
93. Lozano R, Hagerman RJ, Duyzend M, Budimirovic DB, Eichler EE, Tassone F. Genomic studies in fragile X premutation carriers. J Neurodev Disord. 2014; 6:27.
94. Aziz M, Stathopulu E, Callias M, Taylor C, Turk J, Oostra B, Willemsen R, Patton M. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet. 2003; 121B:119-127.
95. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, Hagerman PJ. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet. 2000; 91:144-152.
96. Chonchaiya W, Tassone F, Ashwood P, Hessl D, Schneider A, Campos L, Nguyen DV, Hagerman RJ. Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Hum Genet. 2010; 128:539-548.
97. Seritan A, Cogswell J, Grigsby J. Cognitive dysfunction in FMR1 premutation carriers. Curr Psychiatr Rev. 2012, 9:78-84.
98. Chonchaiya W, Au J, Schneider A, Hessl D, Harris SW, Laird M, Mu Y, Tassone F, Nguyen DV, Hagerman RJ. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012; 131:581-589.
99. Grigsby J, Cornish K, Hocking D, Kraan C, Olichney JM, Rivera SM, Schneider A, Sherman S, Wang JY, Yang JC. The cognitive neuropsychological phenotype of carriers of the FMR1 premutation. J Neurodev Disord. 2014; 6:28.
100. Cornish KM, Hocking DR, Moss SA, Kogan CS. Selective executive markers of at-risk profiles associated with the fragile X premutation. Neurology. 2011; 77:618-622.
101. Myers GF, Mazzocco MM, Maddalena A, Reiss AL. No widespread psychological effect of the fragile X premutation in childhood: Evidence from a preliminary controlled study. J Dev Behav Pediatr. 2001; 22:353-359.
102. Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, Gane L, Tassone F, Hagerman P, Hagerman R. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006; 27(Suppl 2):137-144.
103. Goodlin-Jones BL, Tassone F, Gane LW, Hagerman RJ. Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr. 2004; 25:392-398.
104. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007; 37:738-747.
105. Bailey Jr. DB, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet A. 2008; 146A:2060-2069.
106. Gallego PK, Burris JL, Rivera SM. Visual motion processing deficits in infants with the fragile X premutation. J Neurodev Disord. 2014; 6:29.
107. Franke P, Leboyer M, Gänsicke M, Weiffenbach O, Biancalana V, Cornillet-Lefebre P, Croquette MF, Froster U, Schwab SG, Poustka F, Hautzinger M, Maier W. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res. 1998; 80:113-127.
108. Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Cheung K, Tassone F, Hagerman PJ, Rivera SM. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol psychiatry. 2011; 70:859-865.
109. Losh M, Klusek J, Martin GE, Sideris J, Parlier M, Piven J. Defining genetically meaningful language and personality traits in relatives of individuals with fragile X syndrome and relatives of individuals with autism. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B:660-668.
110. Chen Y, Tassone F, Berman RF, Hagerman PJ, Hagerman RJ, Willemsen R, Pessah IN. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet. 2010; 19:196-208.
111. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010; 19(R1):83-89.
112. Cunningham CL, Martínez Cerdeño V, Navarro Porras E, Prakash AN, Angelastro JM, Willemsen R, Hagerman PJ, Pessah IN, Berman RF, Noctor SC. Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet. 2011; 20:64-79.
113. Hunsaker MR, Goodrich-Hunsaker NJ, Willemsen R, Berman RF. Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation. Behav Brain Res. 2010; 213:263-268.
114. Paul R, Pessah IN, Gane L, Ono M, Hagerman PJ, Brunberg JA, Tassone F, Bourgeois JA, Adams PE, Nguyen DV, Hagerman R. Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. Neurotoxicology. 2010; 31:399-402.
115. Ludwig AL, Espinal GM, Pretto DI, Jamal AL, Arque G, Tassone F, Berman RF, Hagerman PJ. CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. Hum Mol Genet. 2014; 23:3228-3238.
116. Pretto DI, Mendoza-Morales G, Lo J, Cao R, Hadd A, Latham GJ, Durbin-Johnson B, Hagerman R, Tassone F. CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles. J Med Genet. 2014; 51:309-318.
117. Qin M, Entezam A, Usdin K, Huang T, Liu ZH, Hoffman GE, Smith CB. A mouse model of the fragile X premutation: Effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis. Neurobiol Dis. 2011; 42:85-98.
118. Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, Min K, Taylor JP, Paulson HL. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet. 2010; 6:e1001240.
119. Wang YH, Gellibolian R, Shimizu M, Wells RD, Griffith J. Long CCG triplet repeat blocks exclude nucleosomes: A possible mechanism for the nature of fragile sites in chromosomes. J Mol Biol. 1996; 263:511-516.
120. Groh M, Lufino MM, Wade-Martins R, Gromak N. R-loops associated with triplet repeat expansions promote gene silencing in friedreich ataxia and fragile X syndrome. PLoS Genet. 2014; 10:e1004318.
121. Loomis EW, Sanz LA, Chedin F, Hagerman PJ. Transcription-associated R-loop formation across the human FMR1 CGG-repeat region. PLoS Genet. 2014; 10:e1004294.
122. Powell WT, Coulson RL, Gonzales ML, Crary FK, Wong SS, Adams S, Ach RA, Tsang P, Yamada NA, Yasui DH, Chédin F, LaSalle JM. R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Proc Natl Acad Sci U S A. 2013; 110:13938-13943.
123. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ. Protein composition of the intranuclear inclusions of FXTAS. Brain. 2006; 129:256-271.
124. Sofola OA, Jin P, Qin Y, Duan R, Liu H, de Haro M, Nelson DL, Botas J. RNA-binding proteins hnRNP A2/ B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a drosophila model of FXTAS. Neuron. 2007; 55:565-571.
125. Jin P, Duan R, Qurashi A, Qin Y, Tian D, Rosser TC, Liu H, Feng Y, Warren ST. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a drosophila model of fragile X tremor/ataxia syndrome. Neuron. 2007; 55:556-564.
126. Sellier C, Freyermuth F, Tabet R, et al. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 2013; 3:869-880.
127. Qurashi A, Li W, Zhou J, Peng J, Jin P. Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by fragile X premutation rCGG repeats. PLoS Genet. 2011; 7:e1002102.
128. Reddy K, Pearson CE. RAN translation: Fragile X in the running. Neuron. 2013; 778:405-408.
129. Todd PK, Oh SY, Krans A, et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron. 2013; 78:440-455.
130. Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, Hagerman RJ, Tassone F, Tapscott SJ, Filippova GN. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet. 2007; 16:3174-3187.
131. Napoli E, Ross-Inta C, Wong S, Omanska-Klusek A, Barrow C, Iwahashi C, Garcia-Arocena D, Sakaguchi D, Berry-Kravis E, Hagerman R, Hagerman PJ, Giulivi C. Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet. 2011; 20:3079-3092.
132. Ross-Inta C, Omanska-Klusek A, Wong S, Barrow C, Garcia-Arocena D, Iwahashi C, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Giulivi C. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J. 2010; 429:545-552.
133. Loesch DZ, Sherwell S, Kinsella G, Tassone F, Taylor A, Amor D, Sung S, Evans A. Fragile X-associated tremor/ ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet. 2012; 82:88-92.
134. Santa María L, Pugin A, Alliende MA, Aliaga S, Curotto B, Aravena T, Tang HT, Mendoza-Morales G, Hagerman R, Tassone F. FXTAS in an unmethylated mosaic male with fragile X syndrome from chile. Clin Genet. 2014; 86:378-382.
135. Pretto DI, Hunsaker MR, Cunningham CL, Greco CM, Hagerman RJ, Noctor SC, Hall DA, Hagerman PJ, Tassone F. Intranuclear inclusions in a fragile X mosaic male. Transl Neurodegener. 2013; 2:10.
136. Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012; 27:296-300.
137. Hessl D, Rivera S, Koldewyn K, Cordeiro L, Adams J, Tassone F, Hagerman PJ, Hagerman RJ. Amygdala dysfunction in men with the fragile X premutation. Brain. 2007; 130:404-416.
138. Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the united states. Genome Med. 2012; 4:100.
139. Seltzer MM, Barker ET, Greenberg JS, Hong J, Coe C, Almeida D. Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome. Health Psychol. 2012; 31:612-622.
140. Peñagarikano O, Gil A, Télez M, Ortega B, Flores P, Veiga I, Peixoto A, Criado B, Arrieta I. A new insight into fragile X syndrome among basque population. Am J Med Genet A. 2004; 128A:250-255.
141. Bodega B, Bione S, Dalprà L, Toniolo D, Ornaghi F, Vegetti W, Ginelli E, Marozzi A. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod. 2006; 21:952-957.
142. Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005; 117:376-382.
143. Liu Y, Winarni TI, Zhang L, Tassone F, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet. 2013; 84:74-77.
144. Hall DA, Berry-Kravis E, Zhang W, Tassone F, Spector E, Zerbe G, Hagerman PJ, Ouyang B, Leehey MA. FMR1 gray-zone alleles: Association with parkinson's disease in women? Mov Disord. 2011; 26:1900-1906.
145. Loesch DZ, Bui QM, Huggins RM, Mitchell RJ, Hagerman RJ, Tassone F. Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats. J Med Genet. 2007; 44:200-204.
146. Kenna HA, Tartter M, Hall SS, Lightbody AA, Nguyen Q, de los Angeles CP, Reiss AL, Rasgon NL. High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene. American J Med Genet B. 2013; 142b:872-878.
147. Kurz MW, Schlitter AM, Klenk Y, Mueller T, Larsen JP, Aarsland D, Dekomien G. FMR1 alleles in parkinson's disease: Relation to cognitive decline and hallucinations, a longitudinal study. J Geriatr Psychiatry Neurol. 2007; 20:89-92.
148. Kraff J, Tang HT, Cilia R, Canesi M, Pezzoli G, Goldwurm S, Hagerman PJ, Tassone F. Screen for excess FMR1 premutation alleles among males with parkinsonism. Arch Neurol. 2007; 64:1002-1006.
149. Cilia R, Kraff J, Canesi M, Pezzoli G, Goldwurm S, Amiri K, Tang HT, Pan R, Hagerman PJ, Tassone F. Screening for the presence of FMR1 premutation alleles in women with parkinsonism. Arch Neurol. 2009; 66:244-249.
150. Tan EK, Zhao Y, Puong KY, Law HY, Chan LL, Yew K, Shen H, Chandran VR, Yuen Y, Pavanni R, Wong MC, Ng IS. Expanded FMR1 alleles are rare in idiopathic parkinson's disease. Neurogenetics. 2005; 6:51-52.
151. Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord. 2005; 20:230-233.
152. Youings SA, Murray A, Dennis N, Ennis S, Lewis C, McKechnie N, Pound M, Sharrock A, Jacobs P. FRAXA and FRAXE: The results of a five year survey. J Med Genet. 2000; 37:415-421.
153. Crawford DC, Meadows KL, Newman JL, Taft LF, Pettay DL, Gold LB, Hersey SJ, Hinkle EF, Stanfield ML, Holmgreen P, Yeargin-Allsopp M, Boyle C, Sherman SL. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am J Hum Genet. 1999; 64:495-507.
154. Tassone F, Hagerman RJ, Iklé DN, Dyer PN, Lampe M, Willemsen R, Oostra BA, Taylor AK. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet. 1999; 84:250-261.
155. Iwahashi C, Hagerman PJ. Isolation of pathology-associated intranuclear inclusions. Methods Mol Biol. 2008; 463:181-190.
156. Schutzius G, Bleckmann D, Kapps-Fouthier S, di Giorgio F, Gerhartz B, Weiss A. A quantitative homogeneous assay for fragile X mental retardation 1 protein. J Neurodev Disord. 2013; 5:8.
157. LaFauci G, Adayev T, Kascsak R, Kascsak R, Nolin S, Mehta P, Brown WT, Dobkin C. Fragile X screening by quantification of FMRP in dried blood spots by a luminex immunoassay. J Mol Diagn. 2013; 15:508-517.
158. Kovács T, Kelemen O, Kéri S. Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. Psychiatry Res. 2013; 210:690-693.
159. Kelemen O, Kovács T, Kéri S. Contrast, motion, perceptual integrat ion, and neurocogni t ion in schizophrenia: the role of fragile-X related mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:92-97.
160. Hunsaker MR, Greco CM, Tassone F, Berman RF, Willemsen R, Hagerman RJ, Hagerman PJ. Rare intranuclear inclusions in the brains of 3 older adult males with fragile X syndrome: Implications for the spectrum of fragile X-associated disorders. J Neuropathol Exp Neurol. 2011; 70:462-469.
161. Utari A, Adams E, Berry-Kravis E, Chavez A, Scaggs F, Ngotran L, Boyd A, Hessl D, Gane LW, Tassone F, Tartaglia N, Leehey MA, Hagerman RJ. Aging in fragile X syndrome. J Neurodev Disord. 2010; 2:70-76.